Kevin Hrusovsky Chairman & CEO
January, 2018
Kevin Hrusovsky Chairman & CEO January, 2018 Safe Harbor - - PowerPoint PPT Presentation
Kevin Hrusovsky Chairman & CEO January, 2018 Safe Harbor Forward-Looking Statements This presentation and the accompanying oral commentary contain forward-looking statements that are based on our beliefs and assumptions and on
Kevin Hrusovsky Chairman & CEO
January, 2018
2
Safe Harbor
Forward-Looking Statements This presentation and the accompanying oral commentary contain “forward-looking” statements that are based on our beliefs and assumptions and
concerning our possible or assumed future results of operations, business strategies, development plans, regulatory activities, competitive position, potential growth
historical facts and can be identified by terms such as “anticipate,” “believe,” “can,” “continue,” “could,” “enable”, “estimate,” “expect,” “intend,” “may,” “might,” “objective,” “ongoing,” “plan,” “predict,” “project,” “potential,” “should,” “will,” or “would,” or the negative of these terms, or other comparable terminology intended to identify statements about the future. We may not actually achieve the plans, intentions or expectations disclosed in our forward-looking statements. Forward-looking statements involve known and unknown risks, uncertainties, assumptions and other factors that may cause our actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements. Except as required by law, we assume no obligation to update these forward-looking statements publicly, or to update the reasons why actual results could differ materially from those anticipated in the forward-looking statements, even if new information becomes available in the future. The Company has filed with the U.S. Securities and Exchange Commission (the “SEC”) a registration statement (including a prospectus) for the
prospectus in that registration statement, including the Risk Factors set forth therein, and the documents incorporated by reference or filed as exhibits to the registration statement for more complete information about the Company and this offering. You may access these documents for free by visiting EDGAR on the SEC website at www.sec.gov. Alternatively, copies of the preliminary prospectus may be obtained from J.P. Morgan Securities LLC, c/o Broadridge Financial Solutions, 1155 Long Island Avenue, Edgewood, NY 11717, telephone: (866) 803-9204; Leerink Partners LLC, Attention: Syndicate Department, One Federal Street, 37th Floor, Boston, MA 02110, by telephone at (800) 808-7525, ext. 6132 or by email atsyndicate@leerink.com; or Cowen and Company, LLC, c/o Broadridge Financial Solutions, 1155 Long Island Avenue, Edgewood, NY 11717, Attn: Prospectus Department, or by calling (631) 274-2806 or by faxing (631) 254-7140.
3
Marquis Management, Board and Investors
Kevin Hrusovsky Chairman & CEO Martin Madaus, PhD Chairman & CEO Ortho Clinical Diagnostics Douglas Cole, MD Managing Partner Flagship Pioneering Keith L. Crandell Co-Founder & Managing Director ARCH Venture John M. Connolly Senior Advisor Bain Capital Ventures David Walt, PhD Founder Quanterix & Illumina, Harvard Paul Meister Co-founder Liberty Lane Partners Marijn Dekkers, PhD Chairman, Unilever, General Electric BOD
Board
Value Creation – Strong Track Record
Kevin Hrusovsky
Chairman & CEO Mark Roskey, PhD
Commercial
David Duffy, PhD
CTO
Bruce Bal
Operations
Ernie Orticerio
CD & Finance
Elisabeth Colunio
HR
Joe Driscoll
CFO
Brian Keane
General Counsel
Management
Dan Sikkema, PhD
Oncology
Andreas Jermone, PhD
Neurology
4 4
Disruptive Biomarker Technology Enabling Precision Health
Core Simoa T echnology
Multiple Target Markets
Research Diagnostics1 Clinical trials1 Precisionhealth1
Therapeutic Area Focus Scientific and Customer Validation Digital Sensitivity See Health and Disease Processes Earlier Less Invasive Sample Types All Relevant Biomarkers
vs.
Biopsy Blood draw Inflammation Infectious Disease Oncology
Analog Digital
Neurology DNA Proteins RNA
1 Subject to receipt of regulatory approvals or clearances which the company has not applied for to date.Cardiology
Competition
Multiple Instrument Formats Possible
5
Convergence of T echnology and Healthcare
digital analog digital biomarkers
Measuring Life’s Variables
6
20,000
genes
100,000+ proteins
RNA
Molecules of Life; Genotype to Phenotype
Molecules of Life Environmental Factors Affect Health
Drugs Radiation Lifestyle Infections Diet Sleep Exercise Pollution Stress Concussions
Cancer Diabetes
~1975-1990’s ~2000-2013 ~2013-present pg/mL ng/mL fg/mL
ELISA ECL Quanterix
900x
sensitivity increase
Measuring What Could Not Be Seen Before
7
INVASIVENESS
symptoms
Preventative Healthcare
Biopsy, spinal tap
invasive procedures blood saliva urine
healthy I II III IV death STAGE OF DETECTION
sickness begins
biomarker concentration cancer neuro
sick, asymptomatic
cardio infectious disease
HEALTHCARE SICK CARE
biomarker concentration
GOAL Placement of disease categories is for illustration purposes only
8
INVASIVENESS
sickness begins
sick, asymptomatic
symptoms
Preventative Healthcare
biopsy spinal tap blood saliva urine
healthy I II III IV death STAGE OF DETECTION
biomarker concentration
biomarker concentration
Current detection limit Current detection limit New detection limit New detection limit
HEALTHCARE
9.0 pg/ml* 0.01 pg/ml*
* Represents limit of detection for the leading commercially available IL-2 assay and SIMOA’s limit of detection
SICK CARE
>100,000
Proteins expressed in the human body expressed by 20,000 coding human genes
~10,500
Secreted proteins in circulation in human blood
<1,300
Proteins consistently detected by conventional IA tech
~205
FDA-approved IA diagnostic tests
Today
9
Illuminating the Continuum from Health to Disease
Oncology
Potential to be highly predictive of early stage cancer recurrence
Neuro
Potential for diagnosing Alzheimer’s dementia in line with current CSF biomarkers
InfectiousDisease
Significant potential to reduce the spread of infectious disease
Inflammation
TNF-α at LoD levels >100x below traditional IAs
20 pubs 36 markers 89 pubs 49 markers 75 pubs 95 markers
Sensitivity enables researchers to expand into diseases associated with previously undetectable proteins
10
Unprecedented Protein Detection Sensitivity
1Provider Protein
Innotest Ab 42 Innotest Tau Techne IL‐6 Techne TNF‐α ALPCO C‐peptide Techne IL‐10 Millipore INF‐α Genentech IL‐17A Roche/Siemens PSA Ortho p24 Techne IL-5
Normal clinical range (median) Leading ELISA LoD (2.5 SD) Quanterix LoD (2.5 SD)
LoD comparison
Concentration, pg/mL
Assay
Quanterix
Concentration, pg/mL
Average 3000x
Concentration, pg/ml
11
WW COST
Oncology
$350B
DEATHS / YR
9MM
Neurology
$270B 18MM $6B
Cardiology
$470B
ID, Inflammation Other*
$140B
TOTALS:
$1.3T 7MM 15MM ~50MM $38B $9B
Applications
* Other includes validation related to inflammation, technology, immunology and others Source: Health Advances analysis, ASCO, NIH, Kaiser Family Foundation, Miller 2011 J Am Coll Cardiol, O’Donoghue 2014 Ann Intern Med, WHO
$25B
BIOMARKER MARKET
12
Our Product Portfolio
Instruments Assay kits Services
HD-1 Analyzer - $175k list
SR-X - $75k list
Consumables and Ab’s
homebrew / multiplex
In-house and field based
and companion diagnostics
13
SR-X Pre-Launch Traction
14
Long Term (>3 yrs) Near Term (1-3 yrs) Immediate
Strategic Roadmap to $38B Market
*$8B Future Life Science research is inclusive of $3B Life Science Research Today, not net. Also includes pharma services and clinical trials. Note:IA= Immunoassay, IHC = immunohistochemistry, mass spec = mass spectrometry; MS = multiple sclerosis, PSA = prostate-specific antigen, TBI = traumatic brain injury. Source:Health Advances analysis.
Research Today
$3B
Pharma Services & Future Research
$8B*
Diagnostics and Health Screens
Risk/Reward
Quanterix today
$6B POC IA & Molecular $11B Core Lab IA $4B
Mammography MS Monitoring
$1B $2B $1B
PSA Monitoring TBI Monitoring Companion Diagnostics
$2B $1B
Alzheimer’s Diagnosis
$1B
Pancreatic Cancer Screening and Monitoring
15
Pharma Services, LDT, CDx Reinvent drug development Research Discover and validate digital biomarkers IVD Diagnostics, LDT and Health Screens Disrupt healthcare
Global sales channel Menu expansion Benchtop SR-X - Revamped HD-X Phase I, II and III Drug Trials Diagnostics Partners Abbott and BioMerieux
$3B
Clia Lab, Menu
16
Current Landscape Dominated by Few Companies
41% 13% 5% 3% 2% 1%
Other
15%
Manual
20%
*Immunoassay Research, including partners and excluding Diagnostic
IA Research market:
(7% CAGR)
*
Complementary: MASS SPECTROMETRY Indirect Competition: IMAGING
IA + Nucleic Acid Y/E 2016 Installed Base:
14,500
Nucleic Acid
$2B
+
Pharma Services
$2B
+
Future Expansion
$3B
17
Rapid Growth with Compelling Consumable Pull-through
Three-year Growth
($ in millions)
Grew from 0 instruments Jan’14
72 121 53 98 185 58 126 180
2015 2016 2017 est.
Instruments Publications Markers
(cumulative)
2018 Milestones
176
$2.9 $4.4 $7.6
2015 2016 2017E
$12.2 $17.6
Revenue
$22.5- $22.9
= Consumables
Q4 represents a preliminary, unaudited est. of financial
may identify items requiring adjustment to these unaudited financial results.
18
‒ 55 Commercial, 35 R&D/Eng, 25 Mfg / Operations
Business Profile
NA 61% Asia 9% Eur 30%
Instruments 34% Assays 40% Accelerator 26% Pharma/ Biotech/CRO 61% Academia 39% Oncology 16% Neurology 72% Cardiology 5% Infect. Disease 6%
Product Revenue Allocation
(2017 estimate)
$1.6 $3.1 $4.9
2015 2016 2017E
Accelerator Revenue
(millions)
Q4 represents a preliminary, unaudited est. of financial information. We have not finalized the audit of our results of operations for the 3 months and year ended 12/31/17, which may identify items requiring adjustment to these unaudited financial results.
19
Biomarkers Clinical Utility is Transforming Drug Development
Cancer, auto immune and inflammation and neurology
75 300 750 500
2015 2016 2017 Pipeline
Cumulative Trials using QTRX: 2 20
2015 2017
CRO’s using QTRX 7
2015 2017
Trials at QTRX
26.1% 19.1% 15.3% 15.1% 11.1% 9.6% 8.4% 6.6% 5.1%
210%
increase in probability of drug approval
4th Leading Cause of Death in USA
25% 30% 47% 48% 57% 60% 60% 60% 62%
Efficacy
Depression Schizophrenia Cardiac arrhythmia Asthma Diabetes Osteoporosis Hepatitis C AD Cancer
Toxicity
20
Blue Chip Customers
Research Institutions Biopharma Other
21
Rapid Adoption with Early Evidence of High Utilization
# of Instruments Consumable avg. $/yr./instr.1 $117,000 70% Neuro $117,000 70% Infl. & Onco. $200,000 95% Homebrew Applications # of Instruments Consumable avg. $/yr./instr.1 $175,000 95% Homebrew $135,000 70% Neuro $100,000 30% Homebrew Applications
Today avg. is $52K per instr, up from $40K Homebrew revenue per test is 1/3 kits
22
Rapid growth of Clinical Trials in Oncology and Auto Immune
Oncology: Immunotherapy Autoimmune Diseases Cardiovascular Disease Type 2 Diabetes Pulmonary Neurological
“75% of 500+ clinical trials require Quanterix data w/ Luminex”
Ralph McDade, CEO RBM Myriad Genetics (45 Luminex Readers SR-X) Predictive use of efficacy & safety biomarkers
Candidates attrition & refinement Dose selection, PK/PD modeling Efficacy & safety “valid” & putative markers PoM, protocol design Patient stratification Other indications Market differentiation Post approval surveillance
IL-15 IL-17A IL-17f IL-18 IL-23 IFN-α IFN-β CP3B IFN-γ IP-10 MCP-1 TGF-α TNF-α TNF-β TRAIL Homebrew Eotaxin GM-CSF IL-1α IL-1β IL-2 IL-4 IL-5 IL-6 IL-7 IL-8 IL-10 IL-12p40 IL-12p70 IL-13 CP3A Variaplex
Ultrasensitive Digital Biomarkers 20 Inst in Pharma Services Companion Dx
23
2011
2012
2013
2014 2015
2016
2017
Sports/military/concussion TBI Alzheimer's Disease Multiple sclerosis Neurodegeneration (other) Other
JAMA Neurol. 2014;71(6):684-692.
Tau predicts return-to- play following concussion Tau
28 concussed hockey players
AUC 0.91
JAMA Neurol. 2015; Aug 3
Tau (chronic)
70 ex-deployed military personnel
Tau predicts TBI history, and long-term symptoms
(25) (36)
JAMA Neurol 2017; May 1
NF-L
570 patients & HCs cross-sectional
Plasma NF-L exhibits high diagnostic accuracy for Alzheimer’s disease (AUC 0.87)
Neurology Publications – Catalyze Disruption
2x winner
“Concussion”
Starring Will Smith & Alec Baldwin
J Neurotraum Neurol. 2016; Oct 1
NF-L
19 collegiate players (TCU)
NF-L reflects extent of football hit exposure
Neurol Neuroinfl 2016; Aug 2
NF-L
12 patients, longitudinal study
NF-L reflects MS progression
24
Multiple sclerosis Alzheimer's Disease Frontotemporal Dementia Amyotrophic Lateral Sclerosis (ALS) Delirium Traumatic brain injury Concussion Chronic Traumatic Encephalopathy (CTE) Parkinson’s disease Creutzfeldt-Jakob (prion) disease Huntington’s disease Guillain-Barre syndrome Brain hypoxia Stroke Subarachnoid hemorrhage
Neurology Opportunity
Digital biomarkers impacting all areas of brain health:
Tau P-Tau Amyloid β 40 Amyloid β 42 Nf-L BDNF GFAP UCH-L1 NSE TNFa aSynuclein TDP43 Inflammatory Cytokines Multiplex combinations
25
Neurology Customers
1.9 2.8 4.3
2015 2016 2017E
Instrument Sales ($) 1.6 1.9 4.8
2015 2016 2017E
Consumables Sales ($) 0.3 1.1 2.5
2015 2016 2017E
Accelerator Sales ($K) 17 35 48
2015 2016 2017E
Number of Instruments (units) 3 6 22
2015 2016 2017E
Consumable Markers Added 17 75 158
2015 2016 2017E
Accelerator Projects 14 41 85
2015 2016 2017E
Number of 3rd Party Pubs 1 3 8
2015 2016 2017E
Neuro Projects in Trials
26
Neurology Customers PIPELINE
(inc. installed base)
1.9 2.8 4.3
2015 2016 2017E
Instrument Sales ($) 1.6 1.9 4.8
2015 2016 2017E
Consumables Sales ($) 0.3 1.1 2.5
2015 2016 2017E
Accelerator Sales ($K) 17 35 48
2015 2016 2017E
Number of Instruments (units) 3 6 22
2015 2016 2017E
Consumable Markers Added 17 75 158
2015 2016 2017E
Accelerator Projects 14 41 85
2015 2016 2017E
Number of 3rd Party Pubs 1 3 8
2015 2016 2017E
Neuro Projects in Trials
Note: 2017 figures are estimates
Q4 represents a preliminary, unaudited est. of financial information. We have not finalized the audit of our results of operations for the 3 months and year ended 12/31/17, which may identify items requiring adjustment to these unaudited financial results.
“40% lower cost, 60% more accessible, and live 8 years longer productive lives.”
Kevin Hrusovsky Founder & Chair, Powering Precision Health Summit
attendees
luminary speakers
corporate sponsors Speakers from:
Harvard Medical, MD Anderson Cancer Center, Merck, Eli Lilly, NYU, UPenn, NIH, DanaFarber, Yale Medical, Biogen, Cedars Sinai, Myriad RBM,Boston Univ.
Massachusetts Governor Issues Proclamation for Precision Health Awareness Week
12
PPH news articles
402
tweets about PPH
154
live streams
133,000,000
social media impressions
Revolutionary opportunities to detect earlier and improve treatment of:
6,500 Peer-Reviewed Publications
28
Lynchpin
Disrupt Holy Grail
Proven
Product Launches New Answers
Retail
Best in Class $3B to $38Bn1 170+ pubs All Areas $150M Invested 4 2 6 3 5
Proven Management, Bod, Investors and Founder
1 7
Category-defining; Unrivaled Sensitivity Validation: 17/20 top pharma, PPH, 700+ trials Growth & Value; Razor – razor blade, M&A Genotype to phenotype; Drug Development to Dx Methodical market penetration strategy to reward investors Research value backstop with dx / digital disruption potential
Value Differentiator
Poised to Disrupt Healthcare and Create Significant Value
market execution
29
Empowering Personal Health Management Paradigm
* Subject to any required regulatory approvals and clearances, which the company has not applied for to date